Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes

Journal of Clinical Pharmacology

Volumn 50, Issue 8, 2010, Pages 904-913

  Wada, Russ ^b   Rohatagi, Shashank ^a   Small, David ^c   Winters, Kenneth J ^c   Salazar, Daniel E ^a  

^a DAIICHI SANKYO INC   (United States)

^b Quantitative Solutions Inc   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

acute coronary syndromes; modeling and simulation; Platelet aggregation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; ORBOFIBAN; PLACEBO; PRASUGREL; SIBRAFIBAN; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN; BIOLOGICAL MARKER; FIBRINOGEN RECEPTOR; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENDER; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIMULATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; AGE; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; HEMORRHAGE; META ANALYSIS; MORTALITY; MYOCARDIAL INFARCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE;

ACUTE CORONARY SYNDROME; AGE FACTORS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEMORRHAGE; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEX FACTORS;

EID: 77955808081     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009353606     Document Type: Article

References (48)

1. Peters RJG, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003 ; 108: 1682-1687.
2. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006 ; 113: 156-175.
3. Born GVR, Cross MJ The aggregation of blood platelets. J Physiol. 1963 ; 168: 178-195.
4. Egger M., Smith GD, Phillips AN Meta-analysis: principles and procedures. BMJ. 1997 ; 315: 1533-1537.
5. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004 ; 109: 3171-3175.
6. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 ; 354: 1464-1476.
7. Jernberg T., Payne CD, Winters KJ, et al. Prasugrel achieves greater IPA and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 ; 27: 1166-1173.
8. Epic Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994 ; 330: 956-961.
9. Epilog Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997 ; 336: 1689-1696.
10. The RESTORE Investigators. Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997 ; 96: 1445-1453.
11. Capture Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. 1997 ; 349: 1429-1435.
12. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997 ; 349: 1422-1428.
13. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998 ; 339: 436-443.
14. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998 ; 338: 1488-1497.
15. Théroux P., Kouz S., Roy L., et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian Lamifiban Study. Circulation. 1996 ; 94: 899-905.
16. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation. 1998 ; 97: 2386-2395.
17. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Global Organization Network (PARAGON)-B Investigators. Circulation. 2002 ; 105: 316-321.
18. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet. 2001 ; 357: 1915-1924.
19. O'Neill WW, Serruys P., Knudtson M., et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000 ; 342: 1316-1324.
20. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/ IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 ; 102: 149-156.
21. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000 ; 355: 337-345.
22. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001 ; 103: 1727-1733.
23. Steinhubl SR, Berger PB, Mann JT III,, et al. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 ; 288: 2411-2420.
24. Wiviott SD, Antman EM, Winters KJ,, et al. JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005 ; 111: 3366-3373.
25. Gent M., Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989 ; 1: 1215-1220. (Pubitemid 19140324)
26. Balsano F., Rizzon P., Violi F., et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidinanell' Angina Instabile Group. Circulation. 1990 ; 82: 17-26.
27. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 ; 348: 1329-1339.
28. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998 ; 338: 1498-1505.
29. Patti G., Colonna G., Pasceri V., et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005 ; 111: 2099-2106.
30. Simoons ML, de Boer MJ, van den Brand Mjbm, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994 ; 89: 596-603.
31. Saucedo JF, Garza L., Wolford DC, et al. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (The TAM1 Study). Am J Cardiol. 2004 ; 93: 1279-1282. (Pubitemid 38595684)
32. Harrington RA, Kleiman NS, Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995 ; 76: 1222-1227.
33. Kereiakes DJ, Kleiman NS, Ambrose J., et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996 ; 27: 536-542.
34. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 1998 ; 98: 1268-1278.
35. Modi NB, Novotny W., Reimann JD, et al. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/ IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 ; 39: 675-684.
36. Rupprecht HJ, Darius H., Borkowski U., et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998 ; 97: 1046-1052.
37. Leebeek FW, Boersma E., Cannon CP, et al. Oral glycoprotein IIb/ IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J. 2002 ; 23: 444-457.
38. Sy SK, Levenstadt AL A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic. Am J Cardiovasc Drugs. 2004 ; 4: 1-10.
39. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 ; 152: 627-635.
40. Kimmelstiel C., Badar J., Covic L., et al. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res. 2005 ; 116: 55-66.
41. Angiolillo DJ, Fernandez-Ortiz A., Bernardo E., et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol. 2005 ; 96: 1095-1099.
42. Gurbel PA, Bliden KP, Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE Post-Stenting Study. J Am Coll Cardiol. 2005 ; 46: 1820-1826.
43. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006 ; 48: 931-938.
44. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006 ; 4: 542-549.
45. Hochholzer W., Trenk D., Bestehorn H-P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 ; 48: 1742-1750.
46. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006 ; 27: 2420-2425.
47. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 ; 49: 2312-2317.
48. Wiviott SD, Braunwald E., McCabe C., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 ; 357: 2001-2015. (Pubitemid 350106708)